Loading
Call 999 for signs of sepsis, sudden severe breathlessness, a seizure or new confusion; ring the hospital's 24-hour line straight away for a temperature over 37.5 C or below 36 C, for diarrhoea that meets your drug's threshold, for a new cough or breathlessness on pembrolizumab or a deruxtecan drug, or for yellow eyes; use NHS 111 when you cannot reach the team and are not sure.
The wording, situation by situation. Sepsis (999 or A&E, NHS): breathing very fast; confused, slurred speech or not making sense; blue, pale or blotchy skin; a very high or very low temperature, feeling hot or cold to the touch, or shivery; a rash that does not fade when pressed. Infection on chemotherapy (24-hour line, Macmillan): temperature over 37.5 C or below 36 C, shivering, feeling unwell even with a normal temperature. Immune-related reactions on pembrolizumab (24-hour line, Macmillan): more stools than usual or stools at night, tummy cramps; breathlessness, a cough that does not go away, wheeze or fever; yellow skin or eyes; unusual tiredness, headaches, dizziness, thirst. Lung inflammation on trastuzumab deruxtecan or datopotamab deruxtecan (24-hour line): any new cough, breathlessness or fever. Brain symptoms (999): a seizure, sudden severe headache, new weakness or confusion. The NHS says use 111 online or call 111 when you think you need medical help right now and it is not an emergency. This is orientation from public patient pages and guidelines, not advice for your case: your own team's instructions and 24-hour number come first.
Most cancers start in the ducts and drain first to the axillary nodes, which is why the armpit is checked and a sentinel node is sampled.
Same organ: Breast cancer (all types), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Male breast cancer, Ductal carcinoma in situ (DCIS), High-risk early HR-positive breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, HER2-low and HER2-ultralow metastatic breast cancer, Early HER2-positive breast cancer, HER2-positive breast cancer with brain metastases, Early triple-negative breast cancer, Metastatic triple-negative breast cancer, Basal-like 1 triple-negative breast cancer (BL1), Basal-like 2 triple-negative breast cancer (BL2), Mesenchymal triple-negative breast cancer (M), Mesenchymal stem-like triple-negative breast cancer (MSL), Luminal androgen receptor triple-negative breast cancer (LAR), Immunomodulatory triple-negative breast cancer (IM), Metaplastic breast carcinoma, Carcinoma with medullary pattern (medullary breast cancer), Adenoid cystic carcinoma of the breast, Apocrine carcinoma of the breast, Secretory carcinoma of the breast, BRCA-associated triple-negative breast cancer, Inflammatory breast cancer, Paget disease of the nipple, Phyllodes tumour of the breast, Invasive lobular carcinoma of the breast, Invasive breast carcinoma of no special type (invasive ductal carcinoma), Tubular carcinoma of the breast, Mucinous carcinoma of the breast, Papillary carcinomas of the breast (encapsulated, solid and invasive papillary), Invasive cribriform carcinoma of the breast, Invasive breast carcinoma with medullary pattern (medullary carcinoma), Invasive micropapillary carcinoma of the breast, Neuroendocrine neoplasms of the breast, Lobular carcinoma in situ (LCIS)
Showing the organ this term concerns: Triple-negative breast cancer (TNBC).
Shares Febrile neutropenia, Immune-related adverse events (irAEs), Triple-negative breast cancer (TNBC).
Shares Febrile neutropenia, Triple-negative breast cancer (TNBC).
Shares Immune-mediated colitis and diarrhoea, Immune-related adverse events (irAEs).
Shares Interstitial lung disease (ILD) / pneumonitis, Triple-negative breast cancer (TNBC).
Shares Interstitial lung disease (ILD) / pneumonitis, Immune-related adverse events (irAEs).
Shares Immune-mediated colitis and diarrhoea, Febrile neutropenia.
Shares Febrile neutropenia, Triple-negative breast cancer (TNBC).
Shares Immune-related adverse events (irAEs), Triple-negative breast cancer (TNBC).